Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997016208) INFLUENZA VACCINE COMPOSITIONS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/016208 International Application No.: PCT/GB1996/002680
Publication Date: 09.05.1997 International Filing Date: 01.11.1996
Chapter 2 Demand Filed: 30.05.1997
IPC:
A61K 39/145 (2006.01) ,A61K 39/39 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
145
Orthomyxoviridae, e.g. influenza virus
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
39
characterised by the immunostimulating additives, e.g. chemical adjuvants
Applicants:
MEDEVA HOLDINGS B.V. [NL/NL]; Churchill-Laan 223 NL-1078 ED Amsterdam, NL (AllExceptUS)
CHATFIELD, Steven, Neville [GB/GB]; GB (UsOnly)
Inventors:
CHATFIELD, Steven, Neville; GB
Agent:
HUTCHINS, Michael, Richard ; Fry Heath & Spence The Old College 53 High Street Horley Surrey RH6 7BN, GB
Priority Data:
9522351.701.11.1995GB
Title (EN) INFLUENZA VACCINE COMPOSITIONS
(FR) COMPOSITIONS DE VACCINS CONTRE LA GRIPPE
Abstract:
(EN) The invention provides a vaccine composition in the form of a kit comprising a first container containing an antigenic preparation comprising influenza antigen or antigens; and a second container containing an effective adjuvant amount of a chitosan. The antigenic preparation in the first container preferably comprises haemagglutinin and neuraminidase influenza antigens.
(FR) L'invention se rapporte à une composition de vaccin se présentant sous la forme d'un kit et comprenant un premier réceptacle contenant une préparation antigénique constituée d'un ou plusieurs antigènes contre la grippe; et un second réceptacle contenant une quantité efficace d'adjuvant de chitosane. La préparation antigénique du premier réceptacle comprend de préférence les antigènes contre la grippe tels que l'hémagglutinine et la neuraminidase.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
NO19981963ES2174112EP0859632US6136606JP4010462 JPH11515023
CN1201396CA2236538DE000069620001PT859632KR1019990067255NZ320488
AU1996073227DK0859632AU2000056500